AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Living with CML can be challenging. Fortunately, these advances in CML treatment offer hope beyond daily pills.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Prostate-specific membrane antigen (PSMA) gene expression predicts angiogenesis and response to tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC), ...

Taletrectinib can be effective in patients with TKI-naïve or TKI-pretreated advanced NSCLC, a pooled analysis suggests.

Panelists discuss how patient education plays a crucial role in ensuring adherence to tyrosine kinase inhibitor (TKI) therapy by building trust through clear explanations of medications and expected ...

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine ...